Impact of bevacizumab chemotherapy on craniotomy wound healing

TY - JOUR

T1 - Impact of bevacizumab chemotherapy on craniotomy wound healing

AU - Clark, Aaron J

AU - Butowski, Nicholas A

AU - Chang, Susan M

AU - Prados, Michael D

AU - Clarke, Jennifer

AU - Polley, Mei-Yin C

AU - Sughrue, Michael E

AU - McDermott, Michael W

AU - Parsa, Andrew T

AU - Berger, Mitchel S

AU - Aghi, Manish K

N1 - Object. The FDA approval of bevacizumab for recurrent glioblastoma has resulted in its increased use in this patient population. Phase II trials reported 4%-6% impaired wound healing for bevacizumab initiated postoperatively. The effect of preoperative bevacizumab on subsequent craniotomy healing has not been addressed. Methods.

PY - 2011/6/1

Y1 - 2011/6/1

UR - https://mayoclinic.pure.elsevier.com/en/publications/impact-of-bevacizumab-chemotherapy-on-craniotomy-wound-healing-cl

U2 - 10.3171/2010.10.JNS101042

DO - 10.3171/2010.10.JNS101042

M3 - Article

VL - 114

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

ER -